New Drug Development Services
Humanized mice for l/O
Humanized immune system models utilize advanced techniques to transplant human immune cells or precursor cells into mice. This results in the reconstruction of the human immune system within the mouse. Our company offers two primary models: the PBMC model and the CD34+ HSC model.
Our Advanced PBMC Model: Leading the Next Generation of Technology
We have deeply researched and iterated upon the PBMC model, developing a next-generation model with the following unique advantages:
• High Stability: Our PBMC model achieves a stable reconstruction of the immune system, with the success rate of experiment modeling increasing from 50% to 87%. Additionally, the coefficient of variation has been significantly reduced from 120% to 20%.
• Multi-cell Reconstruction: Our PBMC model leads the industry, capable of reconstructing a variety of immune cells, including T cells, B cells, NK cells, macrophages, and DC cells.
• Close to Human Concentration: The number of immune cells reconstructed in our PBMC model can reach or approach the concentration of immune cells in the human body, providing a more realistic environment for drug testing.
Tailored Sub-platforms for Tumor Immunotherapy Drug Development
Depending on specific application needs, we offer the following sub-platforms to our clients:
• iHuPBMC-T: Specifically designed for T cell immunotherapy.
• iHuPBMC-NK: Capable of clinically-level reconstruction of NK cells, suitable for NK cell therapies.
• iHuPBMC-B: Reconstructs B lymphocytes with antibody secretion functionality, suitable for B cell therapies.
• iHuPBMC-MHC/KO: Models on MHC molecule knockout mice, with GVHD occurrence time delayed by over 50%.
• iHuPBMC-OncVax: Co-reconstruction of myeloid cells and lymphoid cells, ideal for the development of tumor vaccines and other immunotherapies requiring antigen presentation.
As an industry leader in humanized immune system models, we are committed to providing our clients with the highest quality of service and solutions. We look forward to collaborating with you and pioneering a new age in tumor immunotherapy drug research and development.